MetLife Investment Management, LLC - CARA THERAPEUTICS INC ownership

CARA THERAPEUTICS INC's ticker is CARA and the CUSIP is 140755109. A total of 134 filers reported holding CARA THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.95 and the average weighting 0.5%.

Quarter-by-quarter ownership
MetLife Investment Management, LLC ownership history of CARA THERAPEUTICS INC
ValueSharesWeighting
Q2 2023$57,039
-42.4%
20,1550.0%0.00%
-100.0%
Q1 2023$98,962
-65.6%
20,155
-24.7%
0.00%
-50.0%
Q4 2022$287,628
+14.7%
26,7810.0%0.00%0.0%
Q3 2022$250,670
+16.4%
26,781
+13.5%
0.00%0.0%
Q2 2022$215,377
-35.0%
23,590
-13.5%
0.00%0.0%
Q1 2022$331,440
+49.4%
27,279
+49.8%
0.00%0.0%
Q4 2021$221,786
-21.2%
18,2090.0%0.00%
-33.3%
Q3 2021$281,329
+8.3%
18,2090.0%0.00%
+50.0%
Q2 2021$259,842
-34.3%
18,2090.0%0.00%
-50.0%
Q1 2021$395,317
+43.5%
18,2090.0%0.00%
+33.3%
Q4 2020$275,502
+18.9%
18,2090.0%0.00%0.0%
Q3 2020$231,710
-25.6%
18,2090.0%0.00%
-25.0%
Q2 2020$311,374
+29.4%
18,2090.0%0.00%
+33.3%
Q1 2020$240,541
-18.0%
18,2090.0%0.00%0.0%
Q4 2019$293,347
-11.9%
18,2090.0%0.00%
-25.0%
Q3 2019$332,861
-1.3%
18,209
+16.1%
0.00%0.0%
Q2 2019$337,163
+9.6%
15,6820.0%0.00%
+33.3%
Q1 2019$307,681
+50.9%
15,6820.0%0.00%0.0%
Q4 2018$203,866
-7.3%
15,682
+36.7%
0.00%0.0%
Q2 2018$220,000
+54.9%
11,4680.0%0.00%
+50.0%
Q1 2018$142,000
+1.4%
11,4680.0%0.00%0.0%
Q4 2017$140,00011,4680.00%
Other shareholders
CARA THERAPEUTICS INC shareholders Q2 2018
NameSharesValueWeighting ↓
Chescapmanager LLC 1,304,903$20,161,0002.86%
KINGDON CAPITAL MANAGEMENT, L.L.C. 715,684$11,057,0001.34%
DISCIPLINED GROWTH INVESTORS INC /MN 1,669,089$25,787,0000.51%
IQ EQ FUND MANAGEMENT (IRELAND) Ltd 156,625$2,420,0000.37%
ALPINE WOODS CAPITAL INVESTORS, LLC 184,632$2,853,0000.30%
Campbell & CO Investment Adviser LLC 42,600$658,0000.21%
FARALLON CAPITAL MANAGEMENT LLC 2,000,000$30,900,0000.14%
PDT Partners, LLC 104,648$1,617,0000.12%
Virtus ETF Advisers LLC 14,798$229,0000.10%
PINNACLE ASSOCIATES LTD 338,922$5,236,0000.10%
View complete list of CARA THERAPEUTICS INC shareholders